Brent Blackburn
Overview
Explore the profile of Brent Blackburn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OMalley S, Miranda Jr R, Book S, Chun T, Liss T, Malcolm R, et al.
Alcohol Alcohol
. 2025 Jan;
60(2).
PMID: 39829301
Aims: We evaluated the safety, efficacy, and patient adherence to oral ANS-6637, a selective, reversible inhibitor of aldehyde dehydrogenase 2 (ALDH2), for treating alcohol use disorder (AUD). Methods: A 3-arm,...
2.
Muhsin A, Blackburn B
Cureus
. 2024 Jun;
16(5):e61103.
PMID: 38919231
Objective The goal of this study is to evaluate treatment times regarding acute ischemic stroke and identify barriers to implementing stroke care at the Ouachita County Medical Center Emergency Department....
3.
Reyes E, Staehr P, Olmsted A, Zeng D, Blackburn B, Cerqueira M, et al.
J Nucl Cardiol
. 2011 May;
18(4):620-7.
PMID: 21553161
Background: There are limited data on the effect of body mass index (BMI) on the actions of fixed-dose regadenoson. The purpose of this study was to determine the effect of...
4.
Yao L, Fan P, Arolfo M, Jiang Z, Olive M, Zablocki J, et al.
Nat Med
. 2010 Aug;
16(9):1024-8.
PMID: 20729865
There is no effective treatment for cocaine addiction despite extensive knowledge of the neurobiology of drug addiction. Here we show that a selective aldehyde dehydrogenase-2 (ALDH-2) inhibitor, ALDH2i, suppresses cocaine...
5.
Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian A
JACC Cardiovasc Imaging
. 2009 Nov;
2(11):1301-9.
PMID: 19909934
Objectives: This study examined the hypothesis that the improvement in myocardial blood flow (MBF) with ranolazine therapy could be detected by serial automated quantitative myocardial perfusion imaging (MPI) in patients...
6.
Hage F, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al.
Am Heart J
. 2009 Apr;
157(4):771-6.
PMID: 19332209
Background: Adenosine and regadenoson increase heart rate (HR) when used as stress agents to produce coronary hyperemia due to direct sympathetic stimulation. We hypothesized that the HR response will be...
7.
Rastogi S, Sharov V, Mishra S, Gupta R, Blackburn B, Belardinelli L, et al.
Am J Physiol Heart Circ Physiol
. 2008 Sep;
295(5):H2149-55.
PMID: 18820026
Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs...
8.
Iskandrian A, Bateman T, Belardinelli L, Blackburn B, Cerqueira M, Hendel R, et al.
J Nucl Cardiol
. 2007 Sep;
14(5):645-58.
PMID: 17826318
Background: Earlier phase 1 and 2 studies have shown that regadenoson has desirable features as a stress agent for myocardial perfusion imaging. Methods And Results: This multicenter, double-blinded phase 3...
9.
Lieu H, Shryock J, von Mering G, Gordi T, Blackburn B, Olmsted A, et al.
J Nucl Cardiol
. 2007 Aug;
14(4):514-20.
PMID: 17679059
Background: Regadenoson is a selective A2A adenosine receptor agonist and vasodilator used to increase the heterogeneity of distribution of coronary blood flow during myocardial perfusion imaging. This study characterized the...
10.
Gordi T, Blackburn B, Lieu H
J Clin Pharmacol
. 2007 Jun;
47(7):825-33.
PMID: 17585115
The authors have investigated the pharmacokinetics and tolerability of regadenoson, a selective A2A adenosine receptor agonist for use in drug-stressed myocardial perfusion imaging in subjects with varying degrees of renal...